| scholarly article | Q13442814 |
| P50 | author | Edwin Bremer | Q39507482 |
| P2093 | author name string | Bart-Jan Kroesen | |
| Wijnand Helfrich | |||
| Linda van Genne | |||
| Douwe Samplonius | |||
| Lou de Leij | |||
| P2860 | cites work | Caspase-10 is an initiator caspase in death receptor signaling | Q24291922 |
| Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. | Q24305298 | ||
| FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis | Q24307362 | ||
| Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 | ||
| Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family | Q24320301 | ||
| Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins | Q24568170 | ||
| Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor | Q24597543 | ||
| Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 | Q28189969 | ||
| FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 | Q28609079 | ||
| A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments | Q30657795 | ||
| Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression | Q33547564 | ||
| Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
| Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro | Q34408151 | ||
| Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. | Q34983320 | ||
| Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens | Q36345949 | ||
| Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells | Q36352524 | ||
| Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug | Q36619067 | ||
| Detection of a putative 30-kDa ligand of the cluster-2 antigen. | Q38312502 | ||
| Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. | Q38479371 | ||
| Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group | Q40568223 | ||
| Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene | Q40648897 | ||
| Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression | Q40657886 | ||
| Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 | ||
| Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. | Q41115802 | ||
| Epitope mapping of SCLC-cluster-2 MAbs and generation of antibodies directed against new EGP-2 epitopes. | Q41507024 | ||
| The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. | Q41517544 | ||
| High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification | Q41730174 | ||
| Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. | Q41747264 | ||
| Episomal vectors rapidly and stably produce high-titer recombinant retrovirus | Q42810400 | ||
| Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models | Q43931271 | ||
| Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study | Q44308902 | ||
| Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene | Q44371834 | ||
| Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. | Q51829884 | ||
| Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H. | Q53972232 | ||
| Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. | Q55473118 | ||
| Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. | Q55476497 | ||
| Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme. | Q55479942 | ||
| Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. | Q55480905 | ||
| Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect | Q64377565 | ||
| Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene | Q64379934 | ||
| The TRAIL DISCussion: It is FADD and caspase-8! | Q73104338 | ||
| Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis | Q73596247 | ||
| The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation | Q73783868 | ||
| The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy | Q73893996 | ||
| Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative | Q74332891 | ||
| Intratumoral genetic heterogeneity in Barrett adenocarcinoma | Q77898310 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 636-645 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Neoplasia | Q2962042 |
| P1476 | title | Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells | |
| P478 | volume | 6 |
| Q46099770 | A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability |
| Q92582493 | A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis |
| Q39744489 | A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. |
| Q28389391 | A review of the past, present, and future directions of neoplasia |
| Q38741706 | An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy. |
| Q90241548 | Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy |
| Q50918966 | CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL. |
| Q28389985 | Coming of Age in the Life of |
| Q37390893 | Death receptors as targets for anti-cancer therapy |
| Q81449950 | EpCAM homologues exhibit epithelial-specific but different expression patterns in the kidney |
| Q38073792 | Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. |
| Q39629670 | Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo |
| Q91716512 | Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation |
| Q28395095 | Neoplasia: Where We Have Been and Where We Are Going |
| Q64376217 | Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein |
| Q36412875 | RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL). |
| Q40472879 | Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci |
| Q39978504 | Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells |
| Q36927030 | Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb. |
| Q39056037 | Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro |
| Q38120535 | Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy |
| Q36792997 | The promise of TRAIL--potential and risks of a novel anticancer therapy |
| Q38554434 | Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody. |
Search more.